{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:04:53Z","timestamp":1789538693434,"version":"build-2803163510"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite significant advances in antiretroviral therapy and prevention strategies, Europe remains off track to meet the UNAIDS 2030 targets of ending HIV as a public health threat. This study explores the implications of failing to meet these targets by quantifying the associated costs and identifying pathways to get back on track.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We adopted a mixed-methods approach across eight European countries. Targeted literature reviews estimated annual and lifetime HIV costs, identified barriers and solutions, and assessed evidence on long-acting injectables (LAIs). Epidemiological data from UNAIDS and ECDC informed projections of HIV prevalence and diagnoses to 2030 under three scenarios. Semi-structured stakeholder consultations validated and expanded the evidence base, and an expert roundtable prioritized solutions and evaluated LAIs' potential impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>If current trends persist, over 98,000 new HIV diagnoses are projected between 2025\u20132030, adding more than \u20ac4 billion in healthcare costs and nearly \u20ac36 billion in lifetime costs. Prevalence-related costs across five countries could reach \u20ac66.3 billion by 2030. Barriers occur at multiple levels, including individual (low risk perception, treatment adherence), societal (stigma, limited community engagement), healthcare (restricted service accessibility), and policy (insufficient funding and fragmented surveillance). LAIs emerged as a promising strategy to overcome adherence challenges and reduce stigma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Without intensified action, Europe faces escalating costs and rising diagnoses. Tackling structural barriers and diversifying treatment options is essential to altering current trajectories. LAIs offer a potentially transformative addition to the HIV care landscape, but achieving their impact requires equitable access, sufficient healthcare capacity, and sustained political commitment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1814445","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:32:06Z","timestamp":1789536726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Avoiding the cost of complacency: barriers and solutions to ending the HIV epidemic in Europe"],"prefix":"10.3389","volume":"14","author":[{"given":"Priscila","family":"Radu","sequence":"first","affiliation":[{"name":"Office of Health Economics (OHE)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hayes","sequence":"additional","affiliation":[{"name":"Office of Health Economics (OHE)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Office of Health Economics (OHE)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mott","sequence":"additional","affiliation":[{"name":"Office of Health Economics (OHE)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hampson","sequence":"additional","affiliation":[{"name":"Office of Health Economics (OHE)","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","unstructured":"Global HIV & AIDS Statistics \u2014 Fact Sheet.\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"Bekker","year":"2023","journal-title":"Nat Rev Dis Primer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(23)02699-5","article-title":"Bruce Richman: building the U=U movement for HIV prevention","volume":"403","author":"Kirby","year":"2024","journal-title":"Lancet."},{"key":"B4","unstructured":"Fast-Track - Ending the HIV Epidemic by 2030\n          \n          2014"},{"key":"B5","year":"2021","journal-title":"Ending Inequalities and Getting on Track to End AIDS by 2030 \u2014 a Summary of the Commitments and Targets within the United Nations General Assembly's 2021 Political Declaration on HIV and AIDS"},{"key":"B6","unstructured":"Progress towards Reaching the Sustainable Development Goals Related to HIV in the European Union and European Economic Area\n          \n          2025"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1097\/QAD.0000000000002887","article-title":"Global estimates for the lifetime cost of managing HIV","volume":"35","author":"Tran","year":"2021","journal-title":"AIDS."},{"key":"B8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/09564624231202287","article-title":"Tackling late HIV diagnosis: lessons from the UK in the COVID-19 era","volume":"35","author":"Boardman","year":"2024","journal-title":"Int J STD AIDS."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/S2468-2667(21)00161-4","article-title":"Barriers to eliminating HIV transmission in England by 2030","volume":"6","author":"Nichols","year":"2021","journal-title":"Lancet Public Health"},{"key":"B10","unstructured":"Kuiper\n              E\n            \n            \n              Brady\n              D\n            \n          \n          Ending the HIV Epidemic in Europe\n          \n          2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijregi.2023.03.006","article-title":"Late HIV diagnosis among migrant women living in Europe \u2014 a systematic review of barriers to HIV testing","volume":"7","author":"Owusu","year":"2023","journal-title":"IJID Reg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.chom.2020.03.020","article-title":"PrEP for HIV prevention: evidence, global scale-up, and emerging options","volume":"27","author":"Celum","year":"2020","journal-title":"Cell Host Microbe."},{"key":"B13","unstructured":"Towards Zero - An Action Plan towards Ending HIV Transmission, AIDS and HIV-Related Deaths in England - 2022 to 2025\n          \n          2021"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1007\/s10461-019-02670-x","article-title":"A qualitative study to identify perceptual barriers to antiretroviral therapy (ART) uptake and adherence in HIV positive people from UK Black African and Caribbean communities","volume":"23","author":"Glendinning","year":"2019","journal-title":"AIDS Behav."},{"key":"B15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/QAI.0000000000003370","article-title":"Barriers and facilitators to long-acting injectable HIV pre-exposure prophylaxis implementation in primary care since its approval in the United States","volume":"95","author":"Keddem","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","article-title":"Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition","volume":"37","author":"Fonner","year":"2023","journal-title":"AIDS."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1097\/QAD.0000000000004144","article-title":"Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines","volume":"39","author":"Viguerie","year":"2025","journal-title":"AIDS."},{"key":"B18","unstructured":"ECDC\n            \n            \n              WHO\n            \n          \n          HIV\/AIDS Surveillance in Europe 2024: 2023 Data\n          \n          2024"},{"key":"B19","unstructured":"European\n              Central Bank\n            \n          \n          ECB Data Portal\n          \n          2025"},{"key":"B20","unstructured":"HIV Estimates with Uncertainty Bounds 1990-Present\n          \n          2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(23)00080-2","article-title":"Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK","volume":"10","author":"Whelan","year":"2023","journal-title":"Lancet HIV."},{"key":"B22","unstructured":"Ending the HIV Epidemic in Spain\n          \n          2019"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/09540121.2020.1781761","article-title":"Experiences of stigma in healthcare settings by people living with HIV in Ireland: a qualitative study","volume":"32","author":"Vaughan","year":"2020","journal-title":"AIDS Care."},{"key":"B24","doi-asserted-by":"publisher","first-page":"106182","DOI":"10.1016\/j.ypmed.2020.106182","article-title":"Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries","volume":"139","author":"de los Rios","year":"2020","journal-title":"Prev Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12954-020-00429-5","article-title":"Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain","volume":"17","author":"Shirley-Beavan","year":"2020","journal-title":"Harm Reduct J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101715","DOI":"10.1016\/j.tmaid.2020.101715","article-title":"Strengthening screening for infectious diseases and vaccination among migrants in Europe: what is needed to close the implementation gaps?","volume":"39","author":"Noori","year":"2021","journal-title":"Travel Med Infect Dis."},{"key":"B27","unstructured":"European\n              HIV\n            \n          \n          Legal Forum. HIV Criminalisation in the EU\n          \n          2023"},{"key":"B28","unstructured":"Paternoster\n              T\n            \n          \n          How did Germany Run Low on Potentially Life-Saving HIV Medication?\n          \n          2024"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1900598","DOI":"10.2807\/1560-7917.ES.2019.24.41.1900598","article-title":"Estimating the \u2018PrEP Gap': how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019","volume":"24","author":"Hayes","year":"2019","journal-title":"Eurosurveillance."},{"key":"B30","unstructured":"European Medicines Agency [Internet]\n          \n          Truvada\n          \n          2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1186\/s12889-023-15540-y","article-title":"Insights into barriers and facilitators in PrEP uptake and use among migrant men and transwomen who have sex with men in Belgium","volume":"23","author":"Van Landeghem","year":"2023","journal-title":"BMC Public Health."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/S2352-3018(23)00334-X","article-title":"Disparities in approaches to ART access in Europe","volume":"11","author":"Tribaudeau","year":"2024","journal-title":"Lancet HIV."},{"key":"B33","unstructured":"ECDC\n            \n            \n              WHO\n            \n          \n          HIV\/AIDS Surveillance in Europe 2023: 2022 Data\n          \n          2023"},{"key":"B34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/hiv.12807","article-title":"HIV testing strategies outside of health care settings in the European Union (EU)\/European Economic Area (EEA): a systematic review to inform European Centre for Disease Prevention and Control guidance","volume":"21","author":"Croxford","year":"2020","journal-title":"HIV Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1800390","DOI":"10.2807\/1560-7917.ES.2019.24.19.1800390","article-title":"Piloting a surveillance system for HIV drug resistance in the European Union","volume":"24","author":"van de Laar","year":"2019","journal-title":"Euro Surveill"},{"key":"B36","unstructured":"HIV\n              Outcomes\n            \n          \n          Recommit to Ending the AIDS Epidemic by 2030: the Need for a New EU Action Plan on HIV\/AIDS\n          \n          2024"},{"key":"B37","unstructured":"Consensus Statement on Actions Needed from the EU to Achieve Ending AIDS and HIV as a Public Health Threat by 2030\n          \n          2024"},{"key":"B38","unstructured":"WHO\n              European Region\n            \n          \n          Regional Action Plans for Ending AIDS and the Epidemics of Viral Hepatitis and Sexually Transmitted Infections 2022\u20132030\n          \n          2023"},{"key":"B39","unstructured":"G7\n              leaders\n            \n          \n          Apulia G7 Leaders' Communiqu\u00e9\n          \n          2024"},{"key":"B40","unstructured":"Alcorn\n              K\n            \n          \n          The Long-Acting HIV Treatment Era is Just Beginning \u2013 HIV Glasgow\n          \n          2024"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1007\/s10461-018-2125-2","article-title":"High rate of discontinuation may diminish PrEP coverage among young men who have sex with men","volume":"22","author":"Morgan","year":"2018","journal-title":"AIDS Behav."},{"key":"B42","unstructured":"Pre-Exposure Prophylaxis for HIV Prevention in Europe and Central Asia\n          \n          2025"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Lancet HIV."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e46767","DOI":"10.2196\/46767","article-title":"Safety and efficacy of long-acting injectable agents for HIV-1: systematic review and meta-analysis","volume":"9","author":"Wang","year":"2023","journal-title":"JMIR Public Health Surveill."},{"key":"B45","unstructured":"Wang\n              H\n            \n            \n              van de Vijver\n              D\n            \n            \n              Jonas\n              K\n            \n            \n              Schroeder\n              M\n            \n            \n              Tosh\n              J\n            \n          \n          Impact of Rapid Long-Acting PrEP Scale-Up among MSM: Closing the Unmet Needs and towards Ending HIV\n          \n          2025"},{"key":"B46","unstructured":"Gandhi\n              M\n            \n          \n          High Virologic Suppression Rates on Long-Acting ART in a Safety-Net Clinic Population\n          \n          2023"},{"key":"B47","doi-asserted-by":"crossref","unstructured":"Durham\n              S\n            \n            \n              Milam\n              A\n            \n            \n              Waer\n              D\n            \n            \n              Chahine\n              E\n            \n          \n          Cabotegravir: the First Long-Acting Injectable for HIV Preexposure Prophylaxis\n          \n          2022","DOI":"10.1177\/10600280221102532"},{"key":"B48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr Opin HIV AIDS."},{"key":"B49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/infdis\/jiaa552","article-title":"Projected impact of concurrently available long-acting injectable and daily-oral human immunodeficiency virus preexposure prophylaxis: a mathematical model","volume":"223","author":"Maloney","year":"2021","journal-title":"J Infect Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/QAI.0000000000003029","article-title":"Projected impact of expanded long-acting injectable PrEP use among men who have sex with men on local HIV epidemics","volume":"91","author":"Balasubramanian","year":"2022","journal-title":"JAIDS J Acquir Immune Defic Syndr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.lana.2022.100416","article-title":"Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate\/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083","volume":"18","author":"Mitchell","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2139\/ssrn.4066619","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/v17091254","article-title":"Real-world experience with long-acting injectable cabotegravir\/rilpivirine in HIV patients with unsuppressed viral load","volume":"17","author":"Trizzino","year":"2025","journal-title":"Viruses."},{"key":"B54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med."},{"key":"B56","unstructured":"The Urgency of Now: AIDS at a Crossroads\n          \n          2024"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2352-3018(24)00212-1","article-title":"Global, regional, and national burden of HIV\/AIDS, 1990\u20132021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021","volume":"11","author":"GBD","year":"2024","journal-title":"Lancet HIV."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1186\/s12889-025-23121-4","article-title":"Global and regional disease burden of HIV\/AIDS from 1990 to 2021 and projections to 2030","volume":"25","author":"Lu","year":"2025","journal-title":"BMC Public Health."},{"key":"B59","unstructured":"UNAIDS\n              Global\n            \n          \n          The Path that Ends AIDS\n          \n          2023"},{"key":"B60","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/phar.2922","article-title":"Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists","volume":"44","author":"Sherman","year":"2024","journal-title":"Pharmacotherapy."},{"key":"B61","unstructured":"El Banhawi\n              H\n            \n            \n              Fong\n              H\n            \n            \n              Hofer\n              M\n            \n            \n              Steuten\n              L\n            \n          \n          Understanding the Full Value of Long Acting Therapies\n          \n          2025"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/j.lanepe.2025.101243","article-title":"Control of HIV across the WHO European region: progress and remaining challenges","volume":"52","author":"Parczewski","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B64","doi-asserted-by":"publisher","first-page":"108058","DOI":"10.1016\/j.jsat.2020.108058","article-title":"Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs","volume":"117","author":"Shrestha","year":"2020","journal-title":"J Subst Abuse Treat."},{"key":"B65","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/COH.0000000000000723","article-title":"Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV","volume":"17","author":"Philbin","year":"2022","journal-title":"Curr Opin HIV AIDS."},{"key":"B66","unstructured":"NHS England: NHS to roll Out First Long-Acting Injection to Prevent HIV\n          \n          2025"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1814445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:32:17Z","timestamp":1789536737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1814445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":66,"alternative-id":["10.3389\/fpubh.2026.1814445"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1814445","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1814445"}}